Cemiplimab Brand Name– LIBTAYO
What is Cemiplimab
Cemiplimab is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC in patients who are not candidates for curative surgery or radiation.
Immune-mediated adverse reactions including colitis, pneumonitis, hepatitis, endocrinopathies, and nephritis have been reported with cemiplimab therapy; treatment with high-dose corticosteroids may be necessary in patients who develop immune-mediated toxicity.
Indications
- squamous cell skin carcinoma
For the treatment of squamous cell skin carcinoma
for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC in patients who are not candidates for curative surgery or curative radiation
Side Effects
- adrenocortical insufficiency
- adrenocortical insufficiency
- anemia
- anorexia
- antibody formation
- aplastic anemia
- asthenia
- asthenia
- back pain
- back pain
- bullous rash
- bullous rash
- colitis
- colitis
- constipation
- constipation
- diabetes mellitus
- diabetic ketoacidosis
- diarrhea
- diarrhea
- elevated hepatic enzymes
- erythema
- erythema
- erythema multiforme
- fatigue
- fatigue
- gastritis
- Guillain-Barre syndrome
- hemolytic anemia
- hemophagocytic lymphohistiocytosis
- hepatitis
- hyperamylasemia
- hypercalcemia
- hypertension
- hyperthyroidism
- hyperthyroidism
- hypoalbuminemia
- hyponatremia
- hypophosphatemia
- hypophysitis
- hypothyroidism
- hypothyroidism
- infection
- infusion-related reactions
- interstitial nephritis
- iritis
- lymphopenia
- maculopapular rash
- maculopapular rash
- meningitis
- musculoskeletal pain
- musculoskeletal pain
- myalgia
- myalgia
- myasthenia gravis
- myelitis
- myocarditis
- nausea
- ocular inflammation
- organ transplant rejection
- pancreatitis
- paresis
- pericarditis
- pneumonitis
- pneumonitis
- pruritus
- purpura
- rash
- rash
- renal failure (unspecified)
- retinal detachment
- rhabdomyolysis
- uveitis
- Vogt-Koyanagi-Harada syndrome
- weakness
Monitoring Parameters
- blood glucose
- LFTs
- pregnancy testing
- serum creatinine/BUN
- thyroid function tests (TFTs)
Contraindications
- adrenal insufficiency
- autoimmune disease
- breast-feeding
- colitis
- contraception requirements
- Crohn’s disease
- hepatitis
- hyperthyroidism
- hypophysitis
- hypothyroidism
- immune-mediated reactions
- inflammatory bowel disease
- infusion-related reactions
- organ transplant
- pneumonitis
- pregnancy
- pregnancy testing
- renal impairment
- reproductive risk
- serious rash
- type 1 diabetes mellitus
- ulcerative colitis
Interactions
- Palifermin
- Penicillamine
- Tuberculin Purified Protein Derivative, PPD
